Next Article in Journal
The Health Benefiting Mechanisms of Virgin Olive Oil Phenolic Compounds
Previous Article in Journal
Phase and Index of Refraction Imaging by Hyperspectral Reflectance Confocal Microscopy
Previous Article in Special Issue
Recent Advances in Neurogenic Small Molecules as Innovative Treatments for Neurodegenerative Diseases
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessEditorial
Molecules 2016, 21(12), 1736; doi:10.3390/molecules21121736

Special Issue: “Molecules against Alzheimer”

1
Pharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074 Würzburg, Germany
2
Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Derek J. McPhee
Received: 9 December 2016 / Revised: 12 December 2016 / Accepted: 12 December 2016 / Published: 16 December 2016
(This article belongs to the Special Issue Molecules against Alzheimer)
View Full-Text   |   Download PDF [169 KB, uploaded 16 December 2016]

Abstract

This Special Issue, entitled “Molecules against Alzheimer”, gathers a number of original articles, short communications, and review articles on recent research efforts toward the development of novel drug candidates, diagnostic agents and therapeutic approaches for Alzheimer’s disease (AD), the most prevalent neurodegenerative disorder and a leading cause of death worldwide. This Special Issue contains many interesting examples describing the design, synthesis, and pharmacological profiling of novel compounds that hit one or several key biological targets, such as cholinesterases, β-amyloid formation or aggregation, monoamine oxidase B, oxidative stress, biometal dyshomeostasis, mitochondrial dysfunction, serotonin and/or melatonin systems, the Wnt/β-catenin pathway, sigma receptors, nicotinamide phosphoribosyltransferase, or nuclear erythroid 2-related factor. The development of novel AD diagnostic agents based on tau protein imaging and the use of lithium or intranasal insulin for the prevention or the symptomatic treatment of AD is also covered in some articles of the Special Issue. View Full-Text
Keywords: Alzheimer’s disease; drug discovery; rational design; hybrid molecules; multi-target-directed molecules; polypharmacology; imaging agents; neuroprotectants; neurogenic molecules Alzheimer’s disease; drug discovery; rational design; hybrid molecules; multi-target-directed molecules; polypharmacology; imaging agents; neuroprotectants; neurogenic molecules
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Decker, M.; Muñoz-Torrero, D. Special Issue: “Molecules against Alzheimer”. Molecules 2016, 21, 1736.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top